1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
Marx, R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J. Oral
Maxillofac. Surg. 2003, 61, 1115–1117. [CrossRef]
Qi, W.X.; Tang, L.N.; He, A.N.; Yao, Y.; Shen, Z. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: A
meta-analysis of seven randomized controlled trials. Int. J. Clin. Oncol. 2014, 19, 403–410. [CrossRef] [PubMed]
Guarneri, V.; Miles, D.; Robert, N.; Diéras, V.; Glaspy, J.; Smith, I.; Thomssen, C.; Biganzoli, L.; Taran, T.; Conte, P. Bevacizumab
and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced
breast cancer. Breast Cancer Res. Treat. 2010, 122, 181–188. [CrossRef] [PubMed]
Ruggiero, S.L.; Dodson, T.B.; Fantasia, J.; Goodday, R.; Aghaloo, T.; Mehrotra, B.; O’Ryan, F. American Association of Oral and
Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J. Oral Maxillofac. Surg. 2014,
72, 1938–1956. [CrossRef] [PubMed]
Ristow, O.; Rückschloß, T.; Müller, M.; Berger, M.; Kargus, S.; Pautke, C.; Engel, M.; Hoffmann, J.; Freudlsperger, C. Is the
conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early
stages? A long-term single-center cohort study. J. Craniomaxillofac. Surg. 2019, 47, 491–499. [CrossRef]
Melea, P.I.; Melakopoulos, I.; Kastritis, E.; Tesseromatis, C.; Margaritis, V.; Dimopoulos, M.A.; Terpos, E. Conservative treatment
of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients. Int. J. Dent. 2014, 2014, 427273. [CrossRef]
[PubMed]
Mauceri, R.; Panzarella, V.; Maniscalco, L.; Bedogni, A.; Licata, M.E.; Albanese, A.; Toia, F.; Cumbo, E.M.G.; Mazzola, G.;
Di Fede, O.; et al. Conservative Surgical Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw with Er,Cr:YSGG Laser
and Platelet-Rich Plasma: A Longitudinal Study. BioMed Res. Int. 2018, 2018, 3982540. [CrossRef]
Stanton, D.C.; Balasanian, E. Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: Review of 33
surgical cases. J. Oral Maxillofac. Surg. 2009, 67, 943–950. [CrossRef]
Kakehashi, H.; Ando, T.; Minamizato, T.; Nakatani, Y.; Kawasaki, T.; Ikeda, H.; Kuroshima, S.; Kawakami, A.; Asahina, I.
Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: Preliminary
findings. Int. J. Oral Maxillofac. Surg. 2015, 44, 1558–1564. [CrossRef]
Fournier, P.; Boissier, S.; Filleur, S.; Guglielmi, J.; Cabon, F.; Colombel, M.; Clézardin, P. Bisphosphonates inhibit angiogenesis
in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002, 62, 6538–6544.
Allen, M.R.; Burr, D.B. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J. Oral
Maxillofac. Surg. 2008, 66, 987–994. [CrossRef]
Lesclous, P.; Abi Najm, S.; Carrel, J.P.; Baroukh, B.; Lombardi, T.; Willi, J.P.; Rizzoli, R.; Saffar, J.L.; Samson, J. Bisphosphonateassociated osteonecrosis of the jaw: A key role of inflammation? Bone 2009, 45, 843–852. [CrossRef] [PubMed]
Ogihara, T.; Matsuzaki, M.; Matsuoka, H.; Shimamoto, K.; Shimada, K.; Rakugi, H.; Umemoto, S.; Kamiya, A.; Suzuki, N.;
Kumagai, H.; et al. The combination therapy of hypertension to prevent cardiovascular events (COPE) trial: Rationale and design.
Hypertens. Res. 2005, 28, 331–338. [CrossRef] [PubMed]
Nishizawa, T.; Cheng, X.W.; Jin, Z.; Obata, K.; Nagata, K.; Hirashiki, A.; Sasaki, T.; Noda, A.; Takeshita, K.; Izawa, H.; et al. Ca2+
channel blocker benidipine promotes coronary angiogenesis and reduces both left-ventricular diastolic stiffness and mortality in
hypertensive rats. J. Hypertens. 2010, 28, 1515–1526. [CrossRef] [PubMed]
Matsuzaki, M.; Ogihara, T.; Umemoto, S.; Rakugi, H.; Matsuoka, H.; Shimada, K.; Abe, K.; Suzuki, N.; Eto, T.; Higaki, J.; et al.
Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: A
randomized controlled trial. J. Hypertens. 2011, 29, 1649–1659. [CrossRef]
Imai, M.; Ayukawa, Y.; Yasunami, N.; Furuhashi, A.; Takemura, Y.; Adachi, N.; Hu, J.; Zhou, X.; Moriyama, Y.; Atsuta, I.; et al.
Effect of a Single Injection of Benidipine-Impregnated Biodegradable Microcarriers on Bone and Gingival Healing at the Tooth
Extraction Socket. Adv. Wound Care 2019, 8, 108–117. [CrossRef] [PubMed]
Nishiya, Y.; Sugimoto, S. Effects of various antihypertensive drugs on the function of osteoblast. Biol. Pharm. Bull. 2001, 24,
628–633. [CrossRef]
Nishiya, Y.; Kosaka, N.; Uchii, M.; Sugimoto, S. A potent 1,4-dihydropyridine L-type calcium channel blocker, benidipine,
promotes osteoblast differentiation. Calcif. Tissue Int. 2002, 70, 30–39. [CrossRef]
Wang, B.; Bi, M.; Zhu, Z.; Wu, L.; Wang, J. Effects of the antihypertensive drug benidipine on osteoblast function in vitro. Exp. Ther.
Med. 2014, 7, 649–653. [CrossRef]
Shimizu, H.; Nakagami, H.; Yasumasa, N.; Mariana, O.K.; Kyutoku, M.; Koriyama, H.; Nakagami, F.; Shimamura, M.; Rakugi, H.;
Morishita, R. Cilnidipine, but not amlodipine, ameliorates osteoporosis in ovariectomized hypertensive rats through inhibition of
the N-type calcium channel. Hypertens. Res. 2012, 35, 77–81. [CrossRef]
Adachi, N.; Ayukawa, Y.; Yasunami, N.; Furuhashi, A.; Imai, M.; Sanda, K.; Atsuta, I.; Koyano, K. Preventive effect of fluvastatin
on the development of medication-related osteonecrosis of the jaw. Sci. Rep. 2020, 10, 5620. [CrossRef] [PubMed]
Sugano, N.; Wakino, S.; Kanda, T.; Tatematsu, S.; Homma, K.; Yoshioka, K.; Hasegawa, K.; Hara, Y.; Suetsugu, Y.; Yoshizawa, T.;
et al. T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy. Kidney Int.
2008, 73, 826–834. [CrossRef] [PubMed]
Yoshikawa, H.; Yoshioka, K.; Nakase, T.; Itoh, K. Stimulation of ectopic bone formation in response to BMP-2 by Rho kinase
inhibitor: A pilot study. Clin. Orthop. Relat. Res. 2009, 467, 3087–3095. [CrossRef] [PubMed]
Pharmaceuticals 2022, 15, 1020
24.
25.
26.
27.
28.
29.
30.
31.
32.
9 of 9
Ma, Z.P.; Liao, J.C.; Zhao, C.; Cai, D.Z. Effects of the 1,4-dihydropyridine L-type calcium channel blocker benidipine on bone
marrow stromal cells. Cell Tissue Res. 2015, 361, 467–476. [CrossRef] [PubMed]
Wang, W.; Li, Z.; Meng, Q.; Zhang, P.; Yan, P.; Zhang, Z.; Zhang, H.; Pan, J.; Zhai, Y.; Liu, Y.; et al. Chronic Calcium Channel
Inhibitor Verapamil Antagonizes TNF-α-Mediated Inflammatory Reaction and Protects Against Inflammatory Arthritis in Mice.
Inflammation 2016, 39, 1624–1634. [CrossRef]
Huang, X.; Li, Y.; Fu, M.; Xin, H.B. Polarizing Macrophages In Vitro. In Macrophages; Methods in Molecular Biology; Humana
Press: New York, NY, USA, 2018; Volume 1784, pp. 119–126. [CrossRef]
Lissner, D.; Schumann, M.; Batra, A.; Kredel, L.I.; Kühl, A.A.; Erben, U.; May, C.; Schulzke, J.D.; Siegmund, B. Monocyte and
M1 Macrophage-induced Barrier Defect Contributes to Chronic Intestinal Inflammation in IBD. Inflamm. Bowel Dis. 2015, 21,
1297–1305. [CrossRef] [PubMed]
Zhu, W.; Xu, R.; Du, J.; Fu, Y.; Li, S.; Zhang, P.; Liu, L.; Jiang, H. Zoledronic acid promotes TLR-4-mediated M1 macrophage
polarization in bisphosphonate-related osteonecrosis of the jaw. FASEB J. 2019, 33, 5208–5219. [CrossRef]
Ono, M.; Ohno, N.; Hasegawa, K.; Tanaka, S.; Komiya, M.; Matsumoto, H.; Fujii, A.; Akimoto, Y. Incidence of gingival overgrowth
caused by calcium channel blockers. Jpn. Soc. Oral. Ther. Pharmacol. 2008, 27, 79–85.
Ichida, M.; Yui, Y.; Yoshioka, K.; Tanaka, T.; Wakamatsu, T.; Yoshikawa, H.; Itoh, K. Changes in cell migration of mesenchymal
cells during osteogenic differentiation. FEBS Lett. 2011, 585, 4018–4024. [CrossRef]
Kobayashi, H.; Kobayashi, S.; Dalrymple, P.D.; Wood, S.G.; Chasseaud, L.F. Absorption, metabolism and excretion after oral
administration of a new Ca antagonist, 14C-benidipine hydrochloride to man. Xenobiotica 1997, 27, 597–608. [CrossRef]
Kaibuchi, N.; Iwata, T.; Yamato, M.; Okano, T.; Ando, T. Multipotent mesenchymal stromal cell sheet therapy for bisphosphonaterelated osteonecrosis of the jaw in a rat model. Acta Biomater. 2016, 42, 400–410. [CrossRef] [PubMed]
...
論文の公開元へ
